By Gilang Cahya 
A groundbreaking study spearheaded by researchers at the UCLA Health Jonsson Comprehensive Cancer Center has unveiled a critical discrepancy in the staging of high-risk, nonmetastatic hormone-sensitive prostate cancer. The findings suggest that a significant proportion of these patients, previously believed to have localized disease based on conventional imaging, may in fact harbor widespread metastatic cancer, necessitating a re-evaluation of current diagnostic and treatment paradigms.
PSMA-PET Imaging Uncovers Widespread Undiagnosed Metastases
The study, meticulously published in the esteemed journal JAMA Network Open, analyzed data from 182 patients with high-risk recurrent prostate cancer who were considered to have disease confined to the prostate and were eligible for the pivotal EMBARK clinical trial. This trial, which demonstrated a significant improvement in metastasis-free survival when enzalutamide, a potent hormone therapy, was added to androgen deprivation therapy, relied on conventional imaging techniques for patient selection. However, the UCLA-led research team employed advanced prostate-specific membrane antigen-positron emission tomography (PSMA-PET) imaging to re-evaluate these patients.
The results were striking: PSMA-PET imaging detected metastatic disease in an astonishing 46% of patients who had previously shown no evidence of cancer spread on traditional scans. Even more concerning, 24% of these individuals exhibited five or more metastatic lesions that had been entirely missed by conventional imaging modalities. This substantial underestimation of disease extent by older imaging technologies raises profound questions about the accuracy of initial staging and its subsequent impact on treatment decisions for a vulnerable patient population.
"Our study demonstrates the critical role of PSMA-PET in accurately staging prostate cancer, which can significantly impact treatment decisions and outcomes," stated Dr. Jeremie Calais, the senior author of the study, director of the Ahmanson Translational Theranostics Division’s clinical research program, and an associate professor at the department of molecular and medical pharmacology at the David Geffen School of Medicine at UCLA. "We anticipated that PSMA-PET would detect more suspicious findings compared to conventional imaging. However, it was informative to uncover such a high number of metastatic findings in a well-defined cohort of patients resembling the EMBARK trial population that was supposed to only include those without metastases."
The Evolution of Prostate Cancer Imaging
For decades, prostate cancer staging has primarily relied on anatomical imaging techniques such as CT scans and bone scans, alongside prostate-specific antigen (PSA) levels and biopsy results. While these methods have been instrumental in guiding treatment, their limitations in detecting small or subtle metastatic deposits have become increasingly apparent.
PSMA-PET imaging represents a significant leap forward in this diagnostic landscape. This advanced technology utilizes highly specific radioactive tracers, known as radiotracers, which are designed to bind to prostate-specific membrane antigen (PSMA). PSMA is a protein that is highly expressed on the surface of prostate cancer cells, including those that have spread beyond the primary tumor. By attaching a radioactive isotope to these tracers, PSMA-PET scans can effectively illuminate even minute clusters of cancer cells, providing functional and molecular information about the disease’s presence and extent.
Unlike conventional imaging, which primarily offers structural details of organs and tissues, PSMA-PET provides a functional map of the cancer’s biological activity. This ability to visualize the molecular characteristics of the cancer cells allows for a far more sensitive and accurate detection of metastatic disease, particularly in cases where tumors are small or located in challenging anatomical areas. The widespread clinical adoption of PSMA-PET has already begun to transform how prostate cancer is managed, yet its full integration into established treatment protocols and clinical trial design is an ongoing process.
Re-evaluating the EMBARK Trial and its Implications
The EMBARK trial, a landmark study in prostate cancer therapeutics, enrolled patients with high-risk nonmetastatic castration-resistant prostate cancer. Its findings demonstrated that the addition of enzalutamide, an androgen receptor inhibitor, to androgen deprivation therapy (ADT) significantly delayed the onset of distant metastases and improved overall survival. However, the patient selection for EMBARK was based on conventional imaging, which the new UCLA study suggests may have inadvertently included a substantial number of patients with undiagnosed metastatic disease.
The retrospective cross-sectional analysis conducted by Dr. Adrien Holzgreve, the first author of the study and a visiting assistant professor at the David Geffen School of Medicine, and his colleagues, aimed to bridge this gap. By re-examining patients who met the criteria for the EMBARK trial but with the superior resolution of PSMA-PET, they aimed to quantify the extent of missed metastases.
The findings from this cohort are particularly significant. The fact that nearly half of the patients, who were deemed nonmetastatic by conventional standards, actually had evidence of metastatic spread when examined with PSMA-PET, strongly suggests that the baseline staging for many such individuals might have been inaccurate. This has profound implications for interpreting the results of trials like EMBARK and for making informed treatment decisions for patients with high-risk disease.
"These results challenge the interpretation of previous studies, like the EMBARK trial, and support the inclusion of PSMA-PET for patient selection in clinical and trial interventions in prostate cancer in future major industry-sponsored clinical trials," Dr. Holzgreve explained. "It also highlights the need to reevaluate treatment strategies and opens the door to potentially curative options for some patients, such as targeted radiotherapy, while raising important questions about integrating new imaging technologies into standard care."
Broader Impact on Treatment Strategies and Patient Outcomes
The discovery that a significant percentage of high-risk nonmetastatic prostate cancer patients actually have metastatic disease has far-reaching consequences for how this cancer is managed. For patients who are identified with previously undetected metastases, treatment strategies may need to be intensified or altered.
Potential for Curative Therapies: The improved detection afforded by PSMA-PET could unlock opportunities for more aggressive, potentially curative treatments. For instance, patients with limited, localized metastatic disease detected by PSMA-PET might be candidates for targeted radiotherapy, such as lutetium-177 PSMA (¹⁷⁷Lu-PSMA) therapy, which has shown promising results in patients with metastatic castration-resistant prostate cancer. Identifying these patients earlier, when their disease burden is lower, could significantly improve treatment efficacy and long-term outcomes.
Revising Clinical Trial Design: The study underscores the urgent need to incorporate PSMA-PET imaging into the design and patient selection criteria for future prostate cancer clinical trials. If trials continue to rely on conventional imaging, they risk enrolling patients who do not accurately represent the intended disease stage, potentially leading to biased results and an underestimation of treatment benefits.
Personalized Medicine and Precision Oncology: PSMA-PET imaging is a cornerstone of personalized medicine in prostate cancer. By providing a more precise picture of the disease’s extent, it allows clinicians to tailor treatment plans to the individual patient’s specific needs and disease characteristics. This aligns with the broader trend towards precision oncology, where treatments are increasingly guided by molecular and imaging biomarkers.
Cost-Effectiveness and Access: While PSMA-PET is a powerful tool, its widespread implementation also raises questions about accessibility and cost-effectiveness. Ensuring that this advanced imaging technology is available to all patients who could benefit from it, regardless of their socioeconomic status or geographic location, will be a critical challenge for healthcare systems. Further research into the long-term cost-effectiveness of PSMA-PET in improving patient outcomes will be essential.
Ongoing Research and Future Directions
The UCLA research team is actively engaged in further investigations to solidify the role of PSMA-PET in prostate cancer management. Their ongoing efforts include analyzing follow-up data from four UCLA trials to meticulously assess how PSMA-PET findings have influenced treatment decisions and, crucially, patient outcomes. This prospective analysis is vital for establishing the real-world impact of this imaging modality.
Furthermore, as part of an international consortium studying over 6,000 patients, the team is rigorously investigating the prognostic value of PSMA-PET. Understanding how PSMA-PET findings correlate with disease progression and survival will further enhance its utility in guiding therapeutic strategies.
"We have good rationales to assume that it is helpful to primarily rely on PSMA-PET findings," Dr. Holzgreve commented. "But more high-quality prospective data would be needed to claim superiority of PSMA-PET for treatment-guidance in terms of patient outcome. However, we are confident PSMA-PET will continue to advance prostate cancer staging and guide personalized therapies."
The findings from this UCLA study serve as a compelling call to action for the medical community. They highlight the limitations of conventional imaging in accurately staging high-risk prostate cancer and emphasize the transformative potential of PSMA-PET imaging. By embracing this advanced technology, clinicians can achieve a more precise diagnosis, make more informed treatment decisions, and ultimately improve the lives of men diagnosed with this common and often aggressive cancer. The era of more accurate and personalized prostate cancer care, guided by sophisticated imaging, is undoubtedly dawning.
